X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Unichem: Strong growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Unichem: Strong growth

Jun 20, 2002

A wider therapeutic reach, increasing presence in exports and restructuring benefits have helped Unichem Labs display robust numbers for FY02. The company's margins have shown steady improvement in the last two years due to product introductions in high growth segments. The company ended FY02 with a 55% growth in net profits.

(Rs m) FY01 FY02 % change
Sales 2,190 2,689 22.7%
Other Income 27 25 -7.0%
Expenditure 1,854 2,233 20.5%
Operating Profit (EBDIT) 337 456 35.3%
Operating Profit Margin (%) 15.4% 16.9%
Interest (net) 50 45 -9.4%
Depreciation 59 66 10.3%
Profit before Tax 254 370 45.4%
Tax 22 61.86 185.1%
Extraordinary Item -34 0 -
Profit after Tax/(Loss) 199 308 55.0%
Net profit margin (%) 9.1% 11.5%
No. of Shares (eoy) (m) 8.5 8.5
Diluted Earnings per share* 23.4 36.2
P/E (at current price) 6.8
*- annualised

The company has been launching products in the high margin segments in the last two years which has helped it enhance its overall profitability margins. The company introduced eight products last fiscal. The company has identified anti-diabetes as its core area of growth going forward. Some of the products introduced include Glitase a drug used to treat diabetes, TG-tor a cholesterol reducing drug, Roff-50 a painkiller, Erix Unichem's version of Pfizer's blockbuster drug Viagra and Nutreva a Protein supplement. It plans to introduce 10 products in the current year.

Last year the company launched two new divisions - Foreva (catering exclusively to women healthcare) and Molecular Generics, which cater to the generics market. The growth drivers were tranquilisers and anti-rheumatics, which registered growth of 18% and 73.4% respectively. While tranquilisers contribute 11.4% to the total turnover, anti-rheumatics contribute around 8.5%. Cardiovascular and CNS also registered healthy growth rates. The growth in the cardiovascular segment was driven by Corvadil-A (hypotensive combinations) and Loprin (anticoagulents). Serta (antidepressant), with a growth rate of 92.9%, was the key growth driver for the CNS category. Cardiovascular and CNS together contribute around 10% to the total turnover.

Unichem is foraying in the UK through a JV with the former directors of the Bioglan group in Ireland. The company will hold a 60% stake in the JV, christened Niche Generics, while the balance 40% will be held by the foreign management team. Niche Generics will buy certain assets of the Bioglan group including the manufacturing facility in Ireland, range of product licenses (market authorisations) representing a present business of approximately 4 m pounds spread across the regulated markets of the European Union and UK. Unichem has already invested 2 m pounds and will invest another 1 m pounds to fund Niche Generics' working capital requirements.

The stock currently trades at Rs 247 at a P/E of 7x FY02 earnings. The company is trading at a discount to its peers in the industry. No doubt that the company has ventured into some high growth areas, however, competition is stiff in these segments and the company will require considerable time and resources to establish its brands here.


Equitymaster requests your view! Post a comment on "Unichem: Strong growth". Click here!

  

More Views on News

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

This is Why You Need to Buy Small Cap Stocks Now(The 5 Minute Wrapup)

Mar 15, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Mar 20, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS